Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2014, Article ID 401915, 10 pages
http://dx.doi.org/10.1155/2014/401915
Review Article

Uveitis and Gender: The Course of Uveitis in Pregnancy

Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, 32 Gisborne Street, East Melbourne, VIC 3002, Australia

Received 25 September 2013; Accepted 9 December 2013; Published 9 January 2014

Academic Editor: H. Nida Sen

Copyright © 2014 Nathalie P. Y. Chiam and Lyndell L. P. Lim. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. P. Buyon, J. L. Nelson, and M. D. Lockshin, “The effects of pregnancy on autoimmune diseases,” Clinical Immunology and Immunopathology, vol. 78, no. 2, pp. 99–104, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. R. L. Wilder, “Hormones, pregnancy, and autoimmune diseases,” Annals of the New York Academy of Sciences, vol. 840, pp. 45–50, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. J. P. Buyon, “The effects of pregnancy on autoimmune diseases,” Journal of Leukocyte Biology, vol. 63, no. 3, pp. 281–287, 1998. View at Google Scholar · View at Scopus
  4. A. Doria, L. Iaccarino, S. Arienti et al., “Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases,” Reproductive Toxicology, vol. 22, no. 2, pp. 234–241, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. I. J. Elenkov, J. Hoffman, and R. L. Wilder, “Does differential neuroendocrine control of cytokine production govern the expression of autoimmune diseases in pregnancy and the postpartum period?” Molecular Medicine Today, vol. 3, no. 9, pp. 379–383, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. I. J. Elenkov, R. L. Wilder, V. K. Bakalov et al., “IL-12, TNF-α, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 10, pp. 4933–4938, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. S. O. Keeling and A. E. Oswald, “Pregnancy and rheumatic disease: “by the book” or ‘by the doc’,” Clinical Rheumatology, vol. 28, no. 1, pp. 1–9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. L. J. Jara, O. Vera-Lastra, J. M. Miranda, M. Alcala, and J. Alvarez-Nemegyei, “Prolactin in human systemic lupus erythematosus,” Lupus, vol. 10, no. 10, pp. 748–756, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Østensen, P. M. Villiger, and F. Förger, “Interaction of pregnancy and autoimmune rheumatic disease,” Autoimmunity Reviews, vol. 11, no. 6-7, pp. A437–A446, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. C.-C. Chan, G. F. Reed, Y. Kim, E. Agrón, and R. R. Buggage, “A correlation of pregnancy term, disease activity, serum female hormones, and cytokines in uveitis,” British Journal of Ophthalmology, vol. 88, no. 12, pp. 1506–1509, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. R. K. Agarwal, C.-C. Chan, B. Wiggert, and R. R. Caspi, “Pregnancy ameliorates induction and expression of experimental autoimmune uveitis,” Journal of Immunology, vol. 162, no. 5, pp. 2648–2654, 1999. View at Google Scholar · View at Scopus
  12. E. F. Foxman, M. Zhang, S. D. Hurst et al., “Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation,” Journal of Immunology, vol. 168, no. 5, pp. 2483–2492, 2002. View at Google Scholar · View at Scopus
  13. M. Akdis, O. Palomares, W. van de Veen, M. van Splunter, and C. A. Akdis, “TH17 and TH22 cells: a confusion of antimicrobial response with tissue inflammation versus protection,” Journal of Allergy and Clinical Immunology, vol. 129, pp. 1438–1449, 2012. View at Google Scholar
  14. E. Bettelli, M. Oukka, and V. K. Kuchroo, “TH-17 cells in the circle of immunity and autoimmunity,” Nature Immunology, vol. 8, no. 4, pp. 345–350, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Furuzawa-Carballeda, M. I. Vargas-Rojas, and A. R. Cabral, “Autoimmune inflammation from the Th17 perspective,” Autoimmunity Reviews, vol. 6, no. 3, pp. 169–175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. B. Torchinsky and J. M. Blander, “T helper 17 cells: discovery, function, and physiological trigger,” Cellular and Molecular Life Sciences, vol. 67, no. 9, pp. 1407–1421, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Ernerudh, G. Berg, and J. Mjösberg, “Regulatory T helper cells in pregnancy and their roles in systemic versus local immune tolerance,” American Journal of Reproductive Immunology, vol. 66, no. 1, pp. 31–43, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. C. K. Wong, C. Y. Ho, E. K. Li, and C. W. K. Lam, “Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus,” Lupus, vol. 9, no. 8, pp. 589–593, 2000. View at Google Scholar · View at Scopus
  19. C. Wang, Y. Tian, B. Lei et al., “Decreased IL-27 expression in association with an increased Th17 response in Vogt-Koyanagi-Harada disease.,” Investigative Ophthalmology & Visual Science, vol. 53, pp. 4668–4675, 2012. View at Google Scholar
  20. D. Yen, J. Cheung, H. Scheerens et al., “IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6,” Journal of Clinical Investigation, vol. 116, no. 5, pp. 1310–1316, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Wang, S. Shao, Z. Jiao, M. Guo, H. Xu, and S. Wang, “The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis,” Rheumatology International, vol. 32, no. 4, pp. 887–893, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Klotz, S. Burgdorf, I. Dani et al., “The nuclear receptor PPARγ selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity,” Journal of Experimental Medicine, vol. 206, no. 10, pp. 2079–2089, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Toldi, J. Rigó Jr., B. Stenczer, B. Vásárhelyi, and A. Molvarec, “Increased prevalence of IL-17-producing peripheral blood lymphocytes in pre-eclampsia,” American Journal of Reproductive Immunology, vol. 66, no. 3, pp. 223–229, 2011. View at Google Scholar · View at Scopus
  24. W.-H. Zhu, C.-Z. Lu, Y.-M. Huang, H. Link, and B.-G. Xiao, “A putative mechanism on remission of multiple sclerosis during pregnancy: estrogen-induced indoleamine 2,3-dioxygenase by dendritic cells,” Multiple Sclerosis, vol. 13, no. 1, pp. 33–40, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. S. S. Soldan, A. I. A. Retuerto, N. L. Sicotte, and R. R. Voskuhl, “Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol,” Journal of Immunology, vol. 171, no. 11, pp. 6267–6274, 2003. View at Google Scholar · View at Scopus
  26. Z. Williams, “Inducing tolerance to pregnancy,” The New England Journal of Medicine, vol. 367, pp. 1159–1161, 2012. View at Google Scholar
  27. J. M. Lipton and A. Catania, “Anti-inflammatory actions of the neuroimmunomodulator α-MSH,” Immunology Today, vol. 18, no. 3, pp. 140–145, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. J. M. Lipton, “Modulation of host defense by the neuropeptide α-MSH,” Yale Journal of Biology and Medicine, vol. 63, no. 2, pp. 173–182, 1990. View at Google Scholar · View at Scopus
  29. J. Harness, A. Cavanagh, H. Morton, and P. McCombe, “A protective effect of early pregnancy factor on experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein,” Journal of the Neurological Sciences, vol. 216, no. 1, pp. 33–41, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. T. B. Tomasi Jr., “Structure and function of alpha-fetoprotein,” Annual Review of Medicine, vol. 28, pp. 453–465, 1977. View at Google Scholar · View at Scopus
  31. E. Matsuura, Y. Kang, H. Kitakawa et al., “Modulation of T cell function by alpha-fetoprotein: an in vivo study on porcine thyroid peroxidase-induced experimental autoimmune thyroiditis in transgenic mice producing human alpha-fetoprotein,” Tumor Biology, vol. 20, no. 3, pp. 162–171, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Vassiliadis, A. Ranella, L. Papadimitriou, A. Makrygiannakis, and I. Athanassakis, “Serum levels of pro- and anti-inflammatory cytokines in non-pregnant women, during pregnancy, labour and abortion,” Mediators of Inflammation, vol. 7, no. 2, pp. 69–72, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Ostensen, R. Lundgren, G. Husby, and O. P. Rekvig, “Studies on humoral immunity in pregnancy: immunoglobulins, alloantibodies and autoantibodies in healthy pregnant women and in pregnant women with rheumatoid disease,” Journal of Clinical and Laboratory Immunology, vol. 11, no. 3, pp. 143–147, 1983. View at Google Scholar · View at Scopus
  34. C. Taguchi, E. Ikeda, N. Hikita, and M. Mochizuki, “A report of two cases suggesting positive influence of pregnancy on uveitis activity,” Nippon Ganka Gakkai zasshi, vol. 103, no. 1, pp. 66–71, 1999. View at Google Scholar · View at Scopus
  35. A. Kubicka-Trz̧ska, “Endogenous uveitis during pregnancy—a report of 4 cases,” Klinika Oczna, vol. 106, no. 3, pp. 328–331, 2004. View at Google Scholar · View at Scopus
  36. K. Yamada, K. Kimoto, J. Ikewaki, K. Nakatsuka, and H. Yatsuka, “A case of recurrent uveitis with remission during pregnancies,” Japanese Journal of Clinical Ophthalmology, vol. 57, no. 3, pp. 311–315, 2003. View at Google Scholar · View at Scopus
  37. P. K. Rabiah and A. T. Vitale, “Noninfectious uveitis and pregnancy,” American Journal of Ophthalmology, vol. 136, no. 1, pp. 91–98, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. L. I. Kump, R. A. Cervantes-Castañeda, S. N. Androudi, C. S. Foster, and W. G. Christen, “Patterns of exacerbations of chronic non-infectious uveitis in pregnancy and puerperium,” Ocular Immunology and Inflammation, vol. 14, no. 2, pp. 99–104, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. N. P. Chiam, A. J. Hall, R. J. Stawell, L. Busija, and L. L. Lim, “The course of uveitis in pregnancy and postpartum,” The British Journal of Ophthalmology, vol. 97, no. 10, pp. 1284–1288, 2013. View at Publisher · View at Google Scholar
  40. D. A. Jabs, “Epidemiology of uveitis,” Ophthalmic Epidemiology, vol. 15, no. 5, pp. 283–284, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. J. H. Barrett, P. Brennan, M. Fiddler, and A. Silman, “Breast-feeding and postpartum relapse in women with rheumatoid and inflammatory arthritis,” Arthritis & Rheumatism, vol. 43, pp. 1010–1015, 2000. View at Google Scholar
  42. J. H. Barrett, P. Brennan, M. Fiddler, and A. J. Silman, “Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy,” Arthritis & Rheumatism, vol. 42, pp. 1219–1227, 1999. View at Google Scholar
  43. L. Matera, M. Mori, M. Geuna, S. Buttiglieri, and G. Palestro, “Prolactin in autoimmunity and antitumor defence,” Journal of Neuroimmunology, vol. 109, no. 1, pp. 47–55, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. S. E. Walker, D. Miller, D. Hill, and G. R. Komatireddy, “Prolactin, a pituitary hormone that modifies immune responses. Proceedings of the Mini-symposium on Prolactin and SLE, held at the 5th International Conference on Systemic Lupus Erythematosus, Cancun, Mexico.,” Lupus, vol. 7, no. 6, pp. 371–375, 1998. View at Publisher · View at Google Scholar · View at Scopus
  45. K. B. Elbourne, D. Keisler, and R. W. McMurray, “Differential effects of estrogen and prolactin on autoimmune disease in the NZB/NZW F1 mouse model of systemic lupus erythematosus,” Lupus, vol. 7, no. 6, pp. 420–427, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. J. L. Nelson and M. Ostenson, “Pregnancy and rheumatoid arthritis,” Rheumatic Disease Clinics of North America, vol. 23, no. 1, pp. 195–212, 1997. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Østensen and P. M. Villiger, “Immunology of pregnancy—pregnancy as a remission inducing agent in rheumatoid arthritis,” Transplant Immunology, vol. 9, no. 2–4, pp. 155–160, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. S. H. Zrour, R. Boumiza, N. Sakly et al., “The impact of pregnancy on rheumatoid arthritis outcome: the role of maternofetal HLA class II disparity,” Joint Bone Spine, vol. 77, no. 1, pp. 36–40, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. E. Musiej-Nowakowska and R. Ploski, “Pregnancy and early onset pauciarticular juvenile chronic arthritis,” Annals of the Rheumatic Diseases, vol. 58, no. 8, pp. 475–480, 1999. View at Google Scholar · View at Scopus
  50. M. Ostensen, “Pregnancy in patients with a history of juvenile rheumatoid arthritis,” Arthritis and Rheumatism, vol. 34, no. 7, pp. 881–887, 1991. View at Google Scholar · View at Scopus
  51. C. Gordon, “Pregnancy and autoimmune diseases,” Best Practice & Research Clinical Rheumatology, vol. 18, pp. 359–379, 2004. View at Google Scholar
  52. R. L. Mayock, R. D. Sullivan, R. R. Greening, and R. Jones Jr., “Sarcoidosis and pregnancy,” Journal of the American Medical Association, vol. 164, no. 2, pp. 158–163, 1957. View at Google Scholar · View at Scopus
  53. D. A. Snyder and H. H. Tessler, “Vogt-Koyanagi-Harada syndrome,” American Journal of Ophthalmology, vol. 90, no. 1, pp. 69–75, 1980. View at Google Scholar · View at Scopus
  54. L. P. Steahly, “Vogt-Koyanagi-Harada syndrome and pregnancy,” Annals of Ophthalmology, vol. 22, no. 2, pp. 59–62, 1990. View at Google Scholar · View at Scopus
  55. Z. Friedman, M. Granat, and E. Neumann, “The syndrome of Vogt-Koyanagi-Harada and pregnancy,” Metabolic Ophthalmology, vol. 4, no. 3, pp. 147–149, 1980. View at Google Scholar · View at Scopus
  56. M. Nohara, K. Norose, and K. Segawa, “Vogt-Koyanagi-Harada disease during pregnancy,” British Journal of Ophthalmology, vol. 79, no. 1, pp. 94–95, 1995. View at Google Scholar · View at Scopus
  57. M. Doi, H. Matsubara, and Y. Uji, “Vogt-Koyanagi-Harada syndrome in a pregnant patient treated with high-dose systemic corticosteroids,” Acta Ophthalmologica Scandinavica, vol. 78, no. 1, pp. 93–96, 2000. View at Publisher · View at Google Scholar · View at Scopus
  58. N. Miyata, M. Sugita, S. Nakamura et al., “Treatment of Vogt-Koyanagi- Harada's disease during pregnancy,” Japanese Journal of Ophthalmology, vol. 45, no. 2, pp. 177–180, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. D. Wakefield, A. Abu El-Asrar, and P. McCluskey, “Treatment of severe inflammatory eye disease in patients of reproductive age and during pregnancy,” Ocular Immunology and Inflammation, vol. 20, pp. 277–287, 2012. View at Google Scholar
  60. C. Y. Chung, A. K. H. Kwok, and K. L. Chung, “Use of opthalmic medications during pregnancy,” Hong Kong Medical Journal, vol. 10, no. 3, pp. 191–195, 2004. View at Google Scholar · View at Scopus
  61. Mycophenolate REMS, “Food and Drug Administration,” 2012, https://www.mycophenolaterems.com/HCPOverview.aspx.
  62. M. Barbhaiya and B. L. Bermas, “Evaluation and management of systemic lupus erythematosus and rheumatoid arthritis during pregnancy,” Clinical Immunology, vol. 149, pp. 225–235, 2013. View at Google Scholar
  63. K. K. Temprano, R. Bandlamudi, and T. L. Moore, “Antirheumatic drugs in pregnancy and lactation,” Seminars in Arthritis and Rheumatism, vol. 35, no. 2, pp. 112–121, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. A. B. Elliott and E. F. Chakravarty, “Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases,” Women's Health, vol. 6, no. 3, pp. 431–442, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Petri, “Immunosuppressive drug use in pregnancy,” Autoimmunity, vol. 36, no. 1, pp. 51–56, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. S. R. J. Taylor, H. Isa, L. Joshi, and S. Lightman, “New developments in corticosteroid therapy for uveitis,” Ophthalmologica, vol. 224, supplement 1, pp. 46–53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. P. Ferrante, A. Ramsey, C. Bunce, and S. Lightman, “Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis,” Clinical and Experimental Ophthalmology, vol. 32, no. 6, pp. 563–568, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. P. Riordan-Eva and S. Lightman, “Orbital floor steroid injections in the treatment of uveitis,” Eye, vol. 8, part 1, pp. 66–69, 1994. View at Google Scholar · View at Scopus
  69. C. J. Helm and G. N. Holland, “The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis,” American Journal of Ophthalmology, vol. 120, no. 1, pp. 55–64, 1995. View at Google Scholar · View at Scopus
  70. I. G. M. Duguid, R. L. Ford, S. E. Horgan, H. M. A. Towler, and S. L. Lightman, “Combined orbital floor betamethasone and depot methylprednisolone in uveitis,” Ocular Immunology and Inflammation, vol. 13, no. 1, pp. 19–24, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. M. L. Dafflon, V. T. Tran, Y. Guex-Crosier, and C. P. Herbort, “Posterior sub-Tenon's steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 237, no. 4, pp. 289–295, 1999. View at Publisher · View at Google Scholar · View at Scopus
  72. V. Tanner, J. J. Kanski, and P. A. Frith, “Posterior sub-Tenon's triamcinolone injections in the treatment of uveitis,” Eye, vol. 12, part 4, pp. 679–685, 1998. View at Google Scholar · View at Scopus
  73. M. Roesel, M. Gutfleisch, C. Heinz, B. Heimes, B. Zurek-Imhoff, and A. Heiligenhaus, “Orbital floor triamcinolone acetonide injections for the management of active non-infectious uveitis,” Eye, vol. 23, no. 4, pp. 910–914, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Raghava, M. Hammond, and U. B. Kompella, “Periocular routes for retinal drug delivery,” Expert Opinion on Drug Delivery, vol. 1, no. 1, pp. 99–114, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. S. Byun and Y.-H. Park, “Complications and safety profile of posterior subtenon injection of triamcinolone acetonide,” Journal of Ocular Pharmacology and Therapeutics, vol. 25, no. 2, pp. 159–162, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Roesel, M. Gutfleisch, C. Heinz, B. Heimes, B. Zurek-Imhoff, and A. Heiligenhaus, “Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study,” Ophthalmic Research, vol. 42, no. 2, pp. 81–86, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. R. J. Antcliff, D. J. Spalton, M. R. Stanford, E. M. Graham, T. J. Fytche, and J. Marshall, “Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study,” Ophthalmology, vol. 108, no. 4, pp. 765–772, 2001. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Young, G. Larkin, M. Branley, and S. Lightman, “Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis,” Clinical and Experimental Ophthalmology, vol. 29, no. 1, pp. 2–6, 2001. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Androudi, E. Letko, M. Meniconi, T. Papadaki, M. Ahmed, and C. S. Foster, “Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema,” Ocular Immunology and Inflammation, vol. 13, no. 2-3, pp. 205–212, 2005. View at Publisher · View at Google Scholar · View at Scopus
  80. R. I. Angunawela, C. J. Heatley, T. H. Williamson et al., “Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: longterm management and outcome,” Acta Ophthalmologica Scandinavica, vol. 83, no. 5, pp. 595–599, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. H. Kok, C. Lau, N. Maycock, P. McCluskey, and S. Lightman, “Outcome of intravitreal triamcinolone in uveitis,” Ophthalmology, vol. 112, no. 11, pp. 1916.e1–1916.e7, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. M. C. Gillies, J. M. Simpson, F. A. Billson et al., “Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial,” Archives of Ophthalmology, vol. 122, no. 3, pp. 336–340, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. S. Tuncer, S. Yilmaz, M. Urgancioglu, and I. Tugal-Tutkun, “Results of Intravitreal Triamcinolone Acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease,” Journal of Ocular Pharmacology and Therapeutics, vol. 23, no. 4, pp. 395–401, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Kramer, R. Ehrlich, M. Snir et al., “Intravitreal injections of triamcinolone acetonide for severe vitritis in patients with incomplete Behcet's disease,” American Journal of Ophthalmology, vol. 138, no. 4, pp. 666–667, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Karacorlu, B. Mudun, H. Ozdemir, S. A. Karacorlu, and E. Burumcek, “Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behçet disease,” American Journal of Ophthalmology, vol. 138, no. 2, pp. 289–291, 2004. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Karacorlu, S. Arf Karacorlu, and H. Ozdemir, “Intravitreal triamcinolone acetonide in Vogt-Koyanagi-Harada syndrome,” European Journal of Ophthalmology, vol. 16, no. 3, pp. 481–483, 2006. View at Google Scholar · View at Scopus
  87. S. Karacorlu, H. Ozdemir, and M. Karacorlu, “Intravitreal triamcinolone acetonide in serpiginous choroiditis,” Japanese Journal of Ophthalmology, vol. 50, no. 3, pp. 290–291, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. H. Ozdemir, M. Karacorlu, and S. Karacorlu, “Intravitreal triamcinolone acetonide in sympathetic ophthalmia,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 243, no. 7, pp. 734–736, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. R. V. P. Chan, B. D. Seiff, H. A. Lincoff, and D. J. Coleman, “Rapid recovery of sympathetic ophthalmia with treatment augmented by intravitreal steroids,” Retina, vol. 26, no. 2, pp. 243–247, 2006. View at Publisher · View at Google Scholar · View at Scopus
  90. J. B. Jonas, “Intravitreal triamcinolone acetonide for treatment of sympathetic ophthalmia,” American Journal of Ophthalmology, vol. 137, no. 2, pp. 367–368, 2004. View at Publisher · View at Google Scholar · View at Scopus
  91. J. B. Jonas and U. H. M. Spandau, “Repeated intravitreal triamcinolone acetonide for chronic sympathetic ophthalmia,” Acta Ophthalmologica Scandinavica, vol. 84, no. 3, p. 436, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Roesel, C. Tappeiner, C. Heinz, J. M. Koch, and A. Heiligenhaus, “Comparison between intravitreal and orbital floor triamcinolone acetonide after phacoemulsification in patients with endogenous uveitis,” American Journal of Ophthalmology, vol. 147, no. 3, pp. 406–412, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. S. Choudhry and S. Ghosh, “Intravitreal and posterior subtenon triamcinolone acetonide in idiopathic bilateral uveitic macular oedema,” Clinical and Experimental Ophthalmology, vol. 35, no. 8, pp. 713–718, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Sallam, R. M. Comer, J. H. Chang et al., “Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children,” Archives of Ophthalmology, vol. 126, no. 2, pp. 200–205, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. Y. Tao and J. B. Jonas, “Intravitreal triamcinolone,” Ophthalmologica, vol. 225, no. 1, pp. 1–20, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. J. H. Kempen, M. M. Altaweel, J. T. Holbrook et al., “Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial,” Ophthalmology, vol. 118, no. 10, pp. 1916–1926, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. C. Lowder, R. Belfort Jr., S. Lightman et al., “Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis,” Archives of Ophthalmology, vol. 129, no. 5, pp. 545–553, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. L. L. Lim, J. R. Smith, and J. T. Rosenbaum, “Retisert Bausch & Lomb/control delivery systems,” Current Opinion in Investigational Drugs, vol. 6, no. 11, pp. 1159–1167, 2005. View at Google Scholar · View at Scopus
  99. M. Østensen, “Antirheumatic therapy and reproduction. The influence on fertility, pregnancy and breast feeding,” Zeitschrift fur Rheumatologie, vol. 65, no. 3, pp. 217–224, 2006. View at Publisher · View at Google Scholar · View at Scopus
  100. L. Park-Wyllie, P. Mazzotta, A. Pastuszak et al., “Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies,” Teratology, vol. 62, pp. 385–392, 2000. View at Google Scholar
  101. P. A. Rosandich, J. T. Kelley III, and D. L. Conn, “Perioperative management of patients with rheumatoid arthritis in the era of biologic response modifiers,” Current Opinion in Rheumatology, vol. 16, no. 3, pp. 192–198, 2004. View at Publisher · View at Google Scholar · View at Scopus
  102. P. A. Greenberger, Y. K. Odeh, M. C. Frederiksen, and A. J. Atkinson Jr., “Pharmacokinetics of prednisolone transfer to breast milk,” Clinical Pharmacology and Therapeutics, vol. 53, no. 3, pp. 324–328, 1993. View at Google Scholar · View at Scopus
  103. L. Ost, G. Wettrell, I. Bjorkhem, and A. Rane, “Prednisolone excretion in human milk,” Journal of Pediatrics, vol. 106, no. 6, pp. 1008–1011, 1985. View at Google Scholar · View at Scopus
  104. B. Nørgård, L. Pedersen, K. Fonager, S. N. Rasmussen, and H. T. Sørensen, “Azathioprine, mercaptopurine and birth outcome: a population-based cohort study,” Alimentary Pharmacology and Therapeutics, vol. 17, no. 6, pp. 827–834, 2003. View at Publisher · View at Google Scholar · View at Scopus
  105. C. Dejaco, C. Mittermaier, W. Reinisch et al., “Azathioprine treatment and male fertility in inflammatory bowel disease,” Gastroenterology, vol. 121, no. 5, pp. 1048–1053, 2001. View at Google Scholar · View at Scopus
  106. C. B. Coulam, T. P. Moyer, N. S. Jiang, and H. Zincke, “Breast-feeding after renal transplantation,” Transplantation Proceedings, vol. 14, no. 3, pp. 605–609, 1982. View at Google Scholar · View at Scopus
  107. V. T. Armenti, J. S. Radomski, M. J. Moritz et al., “Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation,” Clinical transplants, pp. 97–105, 2001. View at Google Scholar · View at Scopus
  108. P. E. Pergola, A. Kancharla, and D. J. Riley, “Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone,” Transplantation, vol. 71, no. 7, pp. 994–997, 2001. View at Google Scholar · View at Scopus
  109. C. Le Ray, A. Coulomb, E. Elefant, R. Frydman, and F. Audibert, “Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations,” Obstetrics and Gynecology, vol. 103, no. 5, pp. 1091–1094, 2004. View at Google Scholar · View at Scopus
  110. S. Di Paolo, A. Schena, L. F. Morrone et al., “Immunologic evaluation during the first year of life of infants born to cyclosporine-treated female kidney transplant recipients: analysis of lymphocyte subpopulations and immunoglobulin serum levels,” Transplantation, vol. 69, no. 10, pp. 2049–2054, 2000. View at Google Scholar · View at Scopus
  111. M. E. Moretti, M. Sgro, D. W. Johnson et al., “Cyclosporine excretion into breast milk,” Transplantation, vol. 75, no. 12, pp. 2144–2146, 2003. View at Publisher · View at Google Scholar · View at Scopus
  112. J. A. Katz, C. Antoni, G. F. Keenan, D. E. Smith, S. J. Jacobs, and G. R. Lichtenstein, “Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis,” American Journal of Gastroenterology, vol. 99, no. 12, pp. 2385–2392, 2004. View at Publisher · View at Google Scholar · View at Scopus
  113. U. Mahadevan, S. Kane, W. J. Sandborn et al., “Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease,” Alimentary Pharmacology and Therapeutics, vol. 21, no. 6, pp. 733–738, 2005. View at Publisher · View at Google Scholar · View at Scopus
  114. B. P. Giroir, K. Peppel, M. Silva, and B. Beutler, “The biosynthesis of tumor necrosis factor during pregnancy: studies with a CAT reporter transgene and TNF inhibitors,” European Cytokine Network, vol. 3, no. 6, pp. 533–538, 1992. View at Google Scholar · View at Scopus
  115. K. L. Hyrich, D. P. M. Symmons, K. D. Watson, and A. J. Silman, “Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register,” Arthritis and Rheumatism, vol. 54, no. 8, pp. 2701–2702, 2006. View at Publisher · View at Google Scholar · View at Scopus
  116. D. J. Wallace and M. H. Weisman, “The use of etanercept and other tumor necrosis factor-α blockers in infertility: it's time to get serious,” Journal of Rheumatology, vol. 30, no. 9, pp. 1897–1899, 2003. View at Google Scholar · View at Scopus
  117. G. M. Enns, E. Roeder, R. T. Chan, Z. Ali-Khan Catts, V. A. Cox, and M. Golabi, “Apparent cyclophosphamide, (cytoxan) embryopathy: a distinct phenotype?” American Journal of Medical Genetics, vol. 86, pp. 237–241, 1999. View at Google Scholar
  118. J. Penso, B. Lippe, R. Ehrlich, and F. G. Smith, “Testicular function in prepubertal and pubertal male patients treated with cyclophosphamide for nephrotic syndrome,” Journal of Pediatrics, vol. 84, no. 6, pp. 831–836, 1974. View at Google Scholar · View at Scopus
  119. W. H. B. Wallace, S. M. Shalet, M. Lendon, and P. H. Morris-Jones, “Male fertility in long-term survivors of childhood acute lymphoblastic leukaemia,” International Journal of Andrology, vol. 14, no. 5, pp. 312–319, 1991. View at Google Scholar · View at Scopus
  120. V. Papadakis, E. Vlachopapadopoulou, K. van Syckle et al., “Gonadal function in young patients successfully treated for Hodgkin disease,” Medical and Pediatric Oncology, vol. 32, pp. 366–372, 1999. View at Google Scholar
  121. P. H. Wiernik and J. H. Duncan, “Cyclophosphamide in human milk,” The Lancet, vol. 1, no. 7705, article 912, 1971. View at Google Scholar · View at Scopus
  122. R. Rahimi, S. Nikfar, A. Rezaie, and M. Abdollahi, “Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis,” Reproductive Toxicology, vol. 25, no. 2, pp. 271–275, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. B. Nørgård, A. E. Czeizel, M. Rockenbauer, J. Olsen, and H. T. Sørensen, “Population-based case control study of the safety of sulfasalazine use during pregnancy,” Alimentary Pharmacology and Therapeutics, vol. 15, no. 4, pp. 483–486, 2001. View at Publisher · View at Google Scholar · View at Scopus
  124. M. Mogadam, W. O. Dobbins III, B. I. Korelitz, and S. W. Ahmed, “Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome,” Gastroenterology, vol. 80, no. 1, pp. 72–76, 1981. View at Google Scholar · View at Scopus
  125. E. Esbjorner, G. Jarnerot, and L. Wranne, “Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation,” Acta Paediatrica Scandinavica, vol. 76, no. 1, pp. 137–142, 1987. View at Google Scholar · View at Scopus
  126. G. Jarnerot and M.-B. Into-Malmberg, “Sulphasalazine treatment during breast feeding,” Scandinavian Journal of Gastroenterology, vol. 14, no. 7, pp. 869–871, 1979. View at Google Scholar · View at Scopus